Reduced intravascular catheter-related infection by routine use of antibiotic-bonded catheters in a surgical intensive care unit
- PMID: 9572020
- DOI: 10.1016/s0732-8893(97)00215-0
Reduced intravascular catheter-related infection by routine use of antibiotic-bonded catheters in a surgical intensive care unit
Abstract
We report a comparative analysis of intravascular catheter-related infection before and after routine use of antibiotic-bonded catheters in an intensive care unit. Cefazolin-bonded catheters were placed in patients requiring catheterization for at least 3 days, or with remote infection, standard catheters at other times. One thousand forty-five catheters (259 patients) over 6 months were compared with 801 (236 antibiotic-bonded, 565 standard) catheters (239 patients) the next 6 months. After use of antibiotic-bonded catheters, we found: 1.7% catheters infected versus 3.7% (p = 0.01); catheter-associated bacteremia 0.1% versus 1.3% (p < 0.005); catheter-related infection rate 4.39 versus 10.73 per 1000 patient days (p < 0.005), and 5.06 versus 11.47 per 1000 catheter days (p < 0.01); and cumulative risk of infection decreased (p < 0.005). Antibiotic-bonded catheters were used with more remote infections (52% versus 27%, p < 0.001), had longer indwelling time (4.4 versus 3.1 days, p = 0.0001), and more were inserted over a guide wire (66% vs. 28%, p < 0.001). In conclusion routine use of antibiotic-bonded catheters was associated with a significant reduction in infectious complications.
Similar articles
-
Reduced intravascular catheter infection by antibiotic bonding. A prospective, randomized, controlled trial.JAMA. 1991 May 8;265(18):2364-8. JAMA. 1991. PMID: 2016833 Clinical Trial.
-
Prevention of neonatal late-onset sepsis associated with the removal of percutaneously inserted central venous catheters in preterm infants.Pediatr Crit Care Med. 2011 Jul;12(4):445-8. doi: 10.1097/PCC.0b013e3182070f5d. Pediatr Crit Care Med. 2011. PMID: 21263371 Clinical Trial.
-
A prospective crossover randomized trial of novobiocin and rifampin prophylaxis for the prevention of intravascular catheter infections in cancer patients treated with interleukin-2.Cancer. 1998 Jan 15;82(2):403-11. doi: 10.1002/(sici)1097-0142(19980115)82:2<412::aid-cncr22>3.0.co;2-0. Cancer. 1998. PMID: 9445199 Clinical Trial.
-
Prevention of vascular catheter-related infections.Neth J Med. 1999 Sep;55(3):92-9. doi: 10.1016/s0300-2977(99)00032-7. Neth J Med. 1999. PMID: 10509065 Review.
-
The patient with intravascular lines.Acta Clin Belg. 1998 Dec;53(6):355-9. Acta Clin Belg. 1998. PMID: 10023144 Review.
Cited by
-
Infections associated with medical devices: pathogenesis, management and prophylaxis.Drugs. 2005;65(2):179-214. doi: 10.2165/00003495-200565020-00003. Drugs. 2005. PMID: 15631541 Review.
-
Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis.Antimicrob Agents Chemother. 2006 Apr;50(4):1268-75. doi: 10.1128/AAC.50.4.1268-1275.2006. Antimicrob Agents Chemother. 2006. PMID: 16569839 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical